GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alkermes PLC (STU:8AK) » Definitions » Cyclically Adjusted PS Ratio

Alkermes (STU:8AK) Cyclically Adjusted PS Ratio : 3.31 (As of May. 23, 2024)


View and export this data going back to . Start your Free Trial

What is Alkermes Cyclically Adjusted PS Ratio?

As of today (2024-05-23), Alkermes's current share price is €22.60. Alkermes's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €6.83. Alkermes's Cyclically Adjusted PS Ratio for today is 3.31.

The historical rank and industry rank for Alkermes's Cyclically Adjusted PS Ratio or its related term are showing as below:

STU:8AK' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.54   Med: 8.1   Max: 23.5
Current: 3.24

During the past years, Alkermes's highest Cyclically Adjusted PS Ratio was 23.50. The lowest was 2.54. And the median was 8.10.

STU:8AK's Cyclically Adjusted PS Ratio is ranked worse than
66.4% of 744 companies
in the Drug Manufacturers industry
Industry Median: 2.12 vs STU:8AK: 3.24

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Alkermes's adjusted revenue per share data for the three months ended in Mar. 2024 was €1.863. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €6.83 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Alkermes Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Alkermes's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alkermes Cyclically Adjusted PS Ratio Chart

Alkermes Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.99 3.59 3.69 3.70 3.77

Alkermes Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.89 4.10 3.59 3.77 3.63

Competitive Comparison of Alkermes's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Alkermes's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alkermes's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alkermes's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Alkermes's Cyclically Adjusted PS Ratio falls into.



Alkermes Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Alkermes's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=22.60/6.83
=3.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alkermes's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Alkermes's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.863/120.9901*120.9901
=1.863

Current CPI (Mar. 2024) = 120.9901.

Alkermes Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.732 100.773 0.879
201409 0.851 100.474 1.025
201412 0.967 99.576 1.175
201503 1.006 99.975 1.217
201506 0.906 100.573 1.090
201509 0.910 100.274 1.098
201512 0.996 99.676 1.209
201603 0.933 99.676 1.133
201606 1.148 101.072 1.374
201609 1.059 100.274 1.278
201612 1.330 99.676 1.614
201703 1.174 100.374 1.415
201706 1.270 100.673 1.526
201709 1.187 100.474 1.429
201712 1.512 100.075 1.828
201803 1.182 100.573 1.422
201806 1.681 101.072 2.012
201809 1.372 101.371 1.638
201812 1.785 100.773 2.143
201903 1.263 101.670 1.503
201906 1.578 102.168 1.869
201909 1.474 102.268 1.744
201912 2.356 102.068 2.793
202003 1.409 102.367 1.665
202006 1.383 101.769 1.644
202009 1.415 101.072 1.694
202012 1.446 101.072 1.731
202103 1.323 102.367 1.564
202106 1.538 103.364 1.800
202109 1.549 104.859 1.787
202112 1.622 106.653 1.840
202203 1.557 109.245 1.724
202206 1.595 112.779 1.711
202209 1.551 113.504 1.653
202212 1.750 115.436 1.834
202303 1.627 117.609 1.674
202306 3.322 119.662 3.359
202309 2.076 120.749 2.080
202312 2.074 120.749 2.078
202403 1.863 120.990 1.863

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Alkermes  (STU:8AK) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Alkermes Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Alkermes's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alkermes (STU:8AK) Business Description

Industry
Traded in Other Exchanges
Address
1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.

Alkermes (STU:8AK) Headlines

No Headlines